Related Experiment Videos
Predicting survival in cost-effectiveness analyses based on clinical trials.
Ulf G Gerdtham1, Niklas Zethraeus
1Department of Community Medicine, Malmö University Hospital, Sweden.
International Journal of Technology Assessment in Health Care
|September 10, 2003
Summary
Predicting health outcomes after clinical trials requires careful model selection. Our study shows that survival predictions and cost-effectiveness analyses are sensitive to the chosen parametric survival model, necessitating thorough sensitivity analysis.
Area of Science:
- Health economics
- Biostatistics
- Clinical trial analysis
Background:
- Randomized controlled trials (RCTs) provide valuable data but have defined endpoints.
- Modeling long-term health effects beyond RCT cessation is crucial for decision-making.
- Parametric survival models are often used for extrapolating trial data.
Purpose of the Study:
- To investigate methods for modeling health effects after randomized controlled trial (RCT) cessation.
- To compare the accuracy of different parametric survival models in predicting long-term outcomes.
- To assess the impact of model choice on cost-effectiveness analysis (CEA).
Main Methods:
- Utilized clinical trial data from patients with severe congestive heart failure.
- Applied various parametric survival models to predict survival post-RCT.
- Compared predicted survival and incremental cost-effectiveness ratios (ICERs) with observed data.
- Conducted sensitivity analyses to evaluate model robustness.
Main Results:
- Survival prediction and cost-effectiveness ratios varied significantly based on the chosen survival model.
- The accuracy of extrapolated results was highly dependent on the selected model.
- Extensive sensitivity analysis is critical for reliable CEA post-RCT.
Conclusions:
- The choice of parametric survival model critically influences predictions of long-term health outcomes and cost-effectiveness.
- Robust sensitivity analysis is essential when extrapolating data beyond the randomized controlled trial period.
- Careful consideration of modeling techniques is required for accurate health economic evaluations.